Clinical trials: Psilocybin
Mental Health
Mindfulness-Assisted Psychedelic Therapy
The goal of this clinical trial is to test psilocybin in combination with mindfulness training in healthy adults. The main question it aims to answer is "Does mindfulness training enhance the effects of psychedelic therapy…
- Trial name
- MAPT (NCT06233344)
- Testing
- Psilocybin plus mindfulness training, Psilocybin
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Anhedonia in Healthy Volunteers, Older Adults (50-90 Years)
A Study of Psychedelics in Healthy Older Adults With Low Well-being
This study is being conducted to understand changes in brain activity following administration of two different drugs (Psilocybin and Dextromethorphan) in older adults with low well-being.
- Trial name
- OAD1 (NCT07386730)
- Testing
- Psilocybin (drug), Dextromethorphan (DXM)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Jennifer Mitchell
Psychedelic Effects in Healthy Volunteers
Psilocybin Administration With 5-HT1a Blockade
The purpose of this study is to assess the effects of 5-HT1A receptor blockade on the acute subjective effects of psilocybin, as measured through subjective survey measures and acute electroencephalography (EEG).
- Trial name
- PsilBlock1 (NCT07565493)
- Testing
- Pindolol, Psilocybin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI
Psilocybin Microdosing on Cognition, Mood and Quality of Life
This study is being conducted to evaluate how of 30 days of intermittently microdosed psilocybin affects mood, cognition, subjective well-being and structural/functional MRI results compared to a placebo.
- Trial name
- NCT07449351
- Testing
- Psliocybin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Yale University
Healthy
Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects
4-bromo-2,5-dimethoxyphenethylamine (2C-B) is a psychoactive substance with reportedly similar acute effects to both the prototypical empathogen 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and the classic psychedelic…
- Trial name
- 2C-B (NCT05523401)
- Testing
- 4-bromo-2,5-dimethoxyphenethylamine (10 mg), 4-bromo-2,5-dimethoxyphenethylamine (20 mg), 4-bromo-2,5-dimethoxyphenethylamine (30 mg)
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Psilocybin
Precision Functional Brain Mapping in Psilocybin
This project will employ functional brain imaging to study the mechanism and immediate and long-term effects of psilocybin, a serotonin receptor 2A agonist, on cortical and cortico-subcortical brain networks in healthy adults.
- Trial name
- Psilocybin PFM (NCT04501653)
- Testing
- Psilocybin, Methylphenidate
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer's Disease
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Background: Normal aging, as well as dementias such as Alzheimer s disease, can cause changes in the brain that affect memory, attention, and thinking.
- Trial name
- NCT07721467
- Testing
- Psilocybin, Cognitive Training
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Depression - Major Depressive Disorder, Anhedonia
Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects
The goal of this clinical trial is to systematically categorize potential prohedonic effects of psilocybin in patients with anhedonia in depression. The main questions it aims to answer are: Primary Objectives 1.
- Trial name
- NCT07490353
- Testing
- Psilocybin (Usona Institute), Risperidone 1 MG, MRI
- Where
- Austria
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Healthy Volunteer
A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers
MLS101 is being developed as a low dose psilocybin, that can be administered to treat neurological and psychiatric conditions. The purpose of this trial is to investigate brain activity, safety, tolerability, and PK of multiple…
- Trial name
- NCT07050368
- Testing
- Psilocybin
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- MycoMedica Life Sciences PBC
Cocaine Use Disorder
Safety Profile of Psilocybin for Cocaine Use Disorder
The purpose of this study is to establish the safe administration of psilocybin in individuals with cocaine use disorder in terms of cardiovascular (e.g., heart rate) and subjective (e.g., mood) effects.
- Trial name
- NCT06102434
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Perception Disturbance, Visual Suppression
Visual Surround Suppression and Perceptual Expectation Under Psilocybin
The prospective pilot study will address the critical need for more precise characterizations of the acute visual effects of the drug psilocybin by measuring the impact of acute psilocybin intoxication on a perceptual task known…
- Conditions
- Perception Disturbance, Visual Suppression, Psychedelic Experiences
- Trial name
- NCT04424225
- Testing
- Psilocybin, Niacin
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Meditation, Microdosing
Optimizing Microdosing and Meditation
The goal of this clinical trial is to test the feasibility of combining meditation with psilocybin microdosing in healthy adults. The main questions it aims to answer are: 1. Recruitment and retention feasibility 2.
- Trial name
- OMM (NCT06560658)
- Testing
- Psilocybin, Meditation
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National University of Natural Medicine
Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD
The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training
The study investigates two groups of participants of the SÄPT therapist's training starting in October 2022. The overall objective is to investigate the risks and benefits of personal experience (PE) with substance-induced…
- Trial name
- TherPsySE (NCT05570708)
- Testing
- MDMA, LSD, psilocybin
- Where
- Switzerland
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Felix Mueller
Healthy
Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects
The acute subjective effects of serotonin (5-HT)2A receptor stimulation with psilocybin in humans are mostly positive. However, negative effects such as anxiety, paranoid thinking, or loss of trust towards other people are common…
- Trial name
- MDMA-Psilo (NCT06884514)
- Testing
- Psilocybin, 3,4-Methylenedioxymethamphetamine
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Psilocybin, Hallucinogens
Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators
This is a pilot study to finalize methods for a larger study being planned for the future. This research is being done to characterize performance of tasks, brain functioning, and the effects of psilocybin in individuals with a…
- Conditions
- Psilocybin, Hallucinogens, Pharmacologic Actions, Central Nervous System Agents
- Trial name
- NCT01988311
- Testing
- psilocybin
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Aging, Longevity
Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life
The LONG-LIFE study is a randomized Phase I, dose-ranging trial designed to evaluate whether psilocybin impacts aging-related biomarkers, cognitive function, and purpose/meaning in life in medically stable older adults.
- Conditions
- Aging, Longevity, Biomarkers of Aging
- Trial name
- LONG-LIFE (NCT07719088)
- Testing
- Psilocybin (Usona Institute)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Charles Raison
Major Depressive Disorder
A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder
The purpose of this study is to determine the safety and tolerability of ascending oral doses of CYB003 in healthy participants with and without major depressive disorder (MDD).
- Trial name
- NCT05385783
- Testing
- CYB003, Psychotherapy, Psychological Support
- Where
- 3 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Cybin IRL Limited
Perception Disorders
Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain
The long-term objective of this project is to characterize how psilocybin affects visual perception and the brain's representation of the visual environment.
- Trial name
- NCT05265546
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
Healthy Participants With Lower-than-average Mental Well-being
Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers
One hundred twenty healthy participants, ages 21 to 70, who experience moderate-to-lower-than-average mental well-being will be evenly randomized into four different study arms, using a 2x2 factorial design.
- Trial name
- SnS (NCT06626139)
- Testing
- Psilocybin, Context 1, Context 2
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Robin Carhart-Harris, PhD, MA
Well-Being, Psychological, Psychedelic Experiences
Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study
This study is exploring how psilocybin (a psychedelic drug) may improve mood and wellbeing. Many people report feeling better after taking psilocybin, but it is not clear why.
- Trial name
- NCT07360301
- Testing
- Psilocybin, Clonidine
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison